ImmuPharma (LON:IMM): Trial update
Market Cap: £45m; Current Price: 37p
First European sites now dosing patients
ImmuPharma issued an update on the progress of its Phase 3 clinical trial of Lupuzor™, its lead programme for the potential treatment of Lupus.
The company confirmed that the first European sites have now commenced dosing Lupus patients.
Recruitment in the study will occur in up to 45 investigator sites. 10 sites in United States and 35 in Europe.
NORTHLAND CAPITAL PARTNERS VIEW: ImmuPharma’s lead programme is progressing to plan, with patients now being dosed in Europe and America. The Phase 3 clinical trial is expected to deliver a read-out by the end of 2017.
Stratex International (LON:STI) – BUY*: Goldstone update
Market Cap: £9m; Current Price: 1.9p; Target Price: 6.6p
Stratex increase loan to Goldstone to US$350,000
Stratex International has increased the unsecured short-term loan to Goldstone Resource, a company that Stratex has a 33.45% interest in, from US$100,000 to US$350,000. All other terms remain the same.
The loan will be used for working capital and to satisfy the amicable settlement between Goldstone and its former CEO Jurie Wessels.
No change to forecasts, rating and price target.
NORTHLAND CAPITAL PARTNERS VIEW: It is positive for both Stratex International and Goldstone Resources (33.45%-owned by Stratex) that an amicable settlement between Goldstone and its former CEO Jurie Wessels has been reached.
ValiRx (LON:VAL) – CORP*: Quarterly update
Market Cap: £5.1m; Current Price: 9.75p
Continued progress
ValiRx issued a Q2 update on its clinical programmes.
The group’s lead compound, VAL201, continues to perform well in its Phase l/ll Clinical Trial in patients with hormone resistant prostate cancer.
To date, no drug related significant adverse events have been reported. Dose escalation has reached therapeutic levels and the studies have shown early indications of efficacy.
Additional Clinical Trial Centers are being integrated into the study to assist with the dose expansion stage of the trial and this enlargement will expedite the production of data in order to complete the trial within the projected and regulatory-agreed time frame.
ValiRx has also begun the process of designing the follow-up full efficacy study of VAL201 in prostate cancer. These will include a review of the most appropriate jurisdictions in which to undertake the work. This process and the development of the actual protocol, with costings and partnerships in place, is expected to be completed and in place by the time that the current Phase I/II trial reports.
In light of the excellent results shown by the compound and the promising pre-clinical evidence of the compound's effect on endometriosis, the Company is continuing the design of the protocol for this indication and to test VAL201 for its in-human potential in the treatment of this debilitating condition.
The protocol and associated partnerships - both commercial and technical - are expected to be in place before the final reporting of the current 'safety and tolerability-focused' clinical trial.
Furthermore, the opportunity for developing and exploiting the compound for a further indication in the treatment of endometriosis or hormone induced abnormal cell growth in women, via partnering and collaboration, is similarly fast approaching and the necessary preparatory steps and conversations are underway.
With regards to ValiRx’s second programme, VAL401, regulatory documentation has been prepared for a clinical Phase II efficacy study. The trial will take place in Georgia, with sites, investigators and facilities now confirmed.
The next steps in the VAL401 regulatory pathway will include receipt of local ethics committee approval prior to receiving the final regulatory go-ahead to recruit patients.
NORTHLAND CAPITAL PARTNERS VIEW: ValiRx continues to progress its two lead programmes. VAL201’s Phase 1/2 trial is moving into its expansion phase with the inclusion of additional clinical trial centres. To date, no drug related significant adverse events have been reported. VAL401 is close to commencing its clinical programme. The trial will take place in Georgia, with sites, investigators and facilities now confirmed.